Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin

被引:137
作者
Garcia-Rodriguez, Consuelo
Levy, Raphael
Arndt, Joseph W.
Forsyth, Charles M.
Razai, Ali
Lou, Jianlong
Geren, Isin
Stevens, Raymond C.
Marks, James D.
机构
[1] Univ Calif San Francisco, Dept Anesthesia & Pharmaceut Chem, San Francisco Gen Hosp, San Francisco, CA 94110 USA
[2] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA
关键词
D O I
10.1038/nbt1269
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Broadening antibody specificity without compromising affinity should facilitate detection and neutralization of toxin and viral subtypes. We used yeast display and a co-selection strategy to increase cross-reactivity of a single chain (sc) Fv antibody to botulinum neurotoxin type A (BoNT/A). Starting with a scFv that binds the BoNT/A1 subtype with high affinity (136 pM) and the BoNT/A2 subtype with low affinity (109 nM), we increased its affinity for BoNT/A2 1,250-fold, to 87 pM, while maintaining high-affinity binding to BoNT/A1 (115 pM). To find the molecular basis for improved cross-reactivity, we determined the X-ray co-crystal structures of wild-type and cross-reactive antibodies complexed to BoNT/A1 at resolutions up to 2.6 angstrom, and measured the thermodynamic contribution of BoNT/A1 and A2 amino acids to wild-type and cross-reactive antibody binding. The results show how an antibody can be engineered to bind two different antigens despite structural differences in the antigen-antibody interface and may provide a general strategy for tuning antibody specificity and cross-reactivity.
引用
收藏
页码:107 / 116
页数:10
相关论文
共 50 条
[1]   Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries [J].
Amersdorfer, P ;
Wong, C ;
Smith, T ;
Chen, S ;
Deshpande, S ;
Sheridan, R ;
Marks, JD .
VACCINE, 2002, 20 (11-12) :1640-1648
[2]   Botulinum toxin as a biological weapon - Medical and public health management [J].
Arnon, SS ;
Schechter, R ;
Inglesby, TV ;
Henderson, DA ;
Bartlett, JG ;
Ascher, MS ;
Eitzen, E ;
Fine, AD ;
Hauer, J ;
Layton, M ;
Lillibridge, S ;
Osterholm, MT ;
O'Toole, T ;
Parker, G ;
Perl, TM ;
Russell, PK ;
Swerdlow, DL ;
Tonat, K .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (08) :1059-1070
[3]   THE CCP4 SUITE - PROGRAMS FOR PROTEIN CRYSTALLOGRAPHY [J].
BAILEY, S .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1994, 50 :760-763
[4]   PASSENGER TRANSGENES REVEAL INTRINSIC SPECIFICITY OF THE ANTIBODY HYPERMUTATION MECHANISM - CLUSTERING, POLARITY, AND SPECIFIC HOT-SPOTS [J].
BETZ, AG ;
RADA, C ;
PANNELL, R ;
MILSTEIN, C ;
NEUBERGER, MS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (06) :2385-2388
[5]   HYPERSENSITIVITY REACTIONS ASSOCIATED WITH BOTULINAL ANTITOXIN [J].
BLACK, RE ;
GUNN, RA .
AMERICAN JOURNAL OF MEDICINE, 1980, 69 (04) :567-570
[6]   Automated kinetic exclusion assays to quantify protein binding interactions in homogeneous solution [J].
Blake, RC ;
Pavlov, AR ;
Blake, DA .
ANALYTICAL BIOCHEMISTRY, 1999, 272 (02) :123-134
[7]   Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity [J].
Boder, ET ;
Midelfort, KS ;
Wittrup, KD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (20) :10701-10705
[8]   Yeast surface display for screening combinatorial polypeptide libraries [J].
Boder, ET ;
Wittrup, KD .
NATURE BIOTECHNOLOGY, 1997, 15 (06) :553-557
[9]  
Bozheyeva G., 1999, FORMER SOVIET BIOL W
[10]   Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate [J].
Byrne, MP ;
Smith, TJ ;
Montgomery, VA ;
Smith, LA .
INFECTION AND IMMUNITY, 1998, 66 (10) :4817-4822